The NT2 project aim to develop new nanotheranostics for the treatment of deep cancers such as prostate and pancreatic cancers. This project is currently in the drug design phase. Preclinical assays are planned for the first semester of 2021. Both prostate and pancreatic cancers are major health issues, especially, pancreatic cancer which is the one with the poorest prognosis. As these organs are too deep to be reached by a Near Infra Red (NIR) laser, photothermal therapy (as used in NT1) cannot be considered as a strategy.

For patients who cannot be operated, a therapeutic option is radiotherapy. The disadvantage of this treatment is that health tissues surrounding the tumor are impacted too by the x-rays. In order to decrease the delivered dose to healthy tissues, radio-enhancers can be used. Radio-enhancers are particles which can interact with X-rays and generate secondary radiations. These radiations as the X-rays are able to generate Reactive Oxygen Species (ROS), mainly by radiolysis, inside the tissues.

Radiotherapy System

Radiation therapy

These ROS induce cells damage leading to death cell. Nanoparticles can be used as radio-enhancers if they are synthetized with a metal having a high atomic number. Thanks to these particles present inside the tumor, the dose of the radiotherapy treatment can be decreased (the interaction x-rays/nanoparticles will compensate the difference) and so the healthy tissues will be less exposed to the radiations.

We are currently working to optimize the couple nanoparticles – irradiation modalities by testing different type of nanoparticles . On contrary of NT1, these nanoparticles will be injected in the blood. Therefore we will also test different functionalization in order to have the best biodistribution in tumours.

Preclinical assay will start in the first semester of 2021 in collaboration with China

  • Our products are made of hybrid materials designed by green chemistry. The NT2 program is funded by the MESR (CIR).

Therapeutic approach:

  • Versatile therapeutic strategy to be reproduced on several cancers

  • Targeted systemic approach (versus complex intra-tumoral with endoscopy)

  • Low volume of NPs injected in one-single injection

  • 3 drug candidates designed, with different NPs and ligands

Scientific partners: GIP CYROI, groupe de santé Clinifutur, ICSM (CNRS Marcoule), Université Sorbonne

Patent: 2016 – Gold nanoparticles and ecological preparation process, Patent FR 16/50520, PCT / FR2017 / 050131